<DOC>
	<DOCNO>NCT01668784</DOCNO>
	<brief_summary>The purpose study compare clinical benefit , measure duration overall survival , Nivolumab vs. Everolimus subject advance metastatic clear-cell renal cell carcinoma receive prior anti-angiogenic therapy</brief_summary>
	<brief_title>Study Nivolumab ( BMS-936558 ) vs. Everolimus Pre-Treated Advanced Metastatic Clear-cell Renal Cell Carcinoma ( CheckMate 025 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men &amp; woman ≥18 year age Histologic confirmation renal cell carcinoma ( RCC ) clearcell component Advanced/metastatic RCC Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion Received 1 2 prior antiangiogenic therapy regimen advance metastatic set No 3 total prior systemic treatment regimen advance metastatic setting , evidence progression last treatment regimen receive within 6 month enrollment Karnofsky Performance Score ≥70 % Any Central Nervous System ( CNS ) metastases history CNS metastases Prior therapy Mammalian target rapamycin ( mTOR ) inhibitor Any active know suspected autoimmune disease Uncontrolled adrenal insufficiency Active chronic liver disease Prior malignancy active within past 3 year , except locally curable cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>